The pharmacokinetics of itraconazole, an orally effective, broad-spectrum, systemic antifungal agent, were evaluated in five healthy male volunteers. Each subject was studied on days 1 and 15 at the following dosages: 100 mg once daily (regimen A), 200 mg once daily (regimen B), and 200 mg twice daily (regimen C). On each study day, itraconazole was administered with a standardized meal. Plasma samples were collected for 72 h postdose, and 24-h urine specimens were obtained. On day 1 of regimen C, plasma samples were collected following the second dose. Samples were assayed for itraconazole by a sensitive, reverse-phase, highperformance liquid chromatography method. Wide intersubject variations in itraconazole concentration in plasma versus time profiles were observed on all study days. Absorption appeared to be slow, with day 1 mean peak itraconazole concentrations in plasma of 110 ng/mI at 2.8 h (regimen A), 272 ng/ml at 3.0 h (regimen B), and 553 ng/ml at 3.4 h (regimen C). Mean peak itraconazole concentrations in plasma on day 15 were 412 ng/ ml at 3.0 h (regimen A), 1,070 ng/ml at 4.4 h (regimen B), and 1,980 ng/ml at 6.0 h (regimen C). The steady state was achieved by day 13. Respective elimination half-lives on days 1 and 15 were 15 and 34 h (regimen A), 20.7, and 36.5 h (regimen B), and 25 and 41.7 h (regimen C), respectively. The areas under the plasma concentration versus time curves (0 to infinity) on day 1 were 1,320 (regimen A), 4,160 (regimen B), and 12,600 ng -h/ml (regimen C) . On day 15, the areas under the plasma concentration versus time curves (0 to 24 h) were 5,330 (regimen A), 15,400 (regimen B), and 39,300 ng-h/ml (regimen C). With the exception of one patient on day 15 of regimen C, itraconazole was not detected in the urine. All data support dose-dependent pharmacokinetic behavior for itraconazole. 
, is a new, orally active triazole antifungal agent (5) . Itraconazole, which was first synthesized in 1980, demonstrates a broad spectrum of activity against a number of fungal species including dermatophytes, Malassesia furfur, Candida species, Aspergillus species, and Histoplasma capsulatum var. capsulatum (1) . The mechanism of action of itraconazole appears similar to that of ketoconazole, involving inhibition of cell membrane ergosterol synthesis. However, itraconazole differs from ketoconazole in that it demonstrates a high degree of lipophilicity and a lack of endocrine-related side effects.
Itraconazole is an extremely weak base (PKa = 3.7) which is virtually unionized at physiological pH (2) . Since itraconazole is soluble only under extremely acidic conditions, only an oral dosage formulation is currently available for use. The isomers of itraconazole have not yet been separated; thus, in all studies to date the racemic mixture has been evaluated.
The objective of this study was to evaluate the pharmacokinetic behavior of itraconazole following acute and chronic oral administration at daily dosages ranging from 100 to 400 mg. * (Tables 1 and 2 ). The mean (± standard deviation) peak itraconazole concentration in plasma (Cmax) on day 1 of the 100-mg dose per day was 110 ± 57.5 ng/ml, on day 1 of the 200-mg dose per day it was 272 ± 81.2 ng/ml, and following the second dose on day 1 of the 200-mg dose twice a day it was 553 ± 179 ng/ml; the values were observed at 2.8 ± 1.1, 3.0 ± 0.7, and 3.4 ± 0.5 h, respectively (Tmax). Significant accumulation was observed with chronic dosing, as shown by increasing trough concentrations in plasma on days 7, 10, 13, and 15 (Table 3 ). Figure 2 illustrates Limited pharmacokinetic data exist for itraconazole in humans (2) . As reported in animal studies, itraconazole absorption in human volunteers is improved when the oral capsules are given with food rather than in a fasting state. However, absolute bioavailability analysis is not currently possible in the absence of an intravenous product. Extensive tissue binding has been observed after a single 200-mg dose in women undergoing hysterectomy (4) .
Our results demonstrate a broad range of itraconazole concentrations in plasma following oral doses of 100 mg per day. Similar variances were observed following doses of 200 mg per day and 200 mg twice a day, the dosage commonly used in clinical trials of systemic itraconazole therapy.
Recognizing the effect of food on absorption, all subjects received their dosages with a standardized meal. The second peaks observed with a dose of 200 mg twice daily may be representative of enterohepatic recirculation of unchanged itraconazole. This has not been studied carefully, but it has been demonstrated in rats (2).
Heykants and co-workers (2) have reported that oral absorption and bioavailability of itraconazole are a function of dose. After oral doses of 50, 100, and 200 mg, increases in the AUC and Cmax were nonlinear, suggesting a saturation of the first-pass metabolism process in the liver. Our findings support this nonlinearity following both single and chronic dosing at 100, 200, and 400 mg per day. The mean Cmax after a dose of 200 mg per day was 147% higher than the Cmax after a dose of 100 mg per day on day 1 and 160% higher on day 15. However, this disproportionate increase in mean Cmax was not observed between doses of 200 mg per day and 200 mg twice a day, possibly because of the twice daily dosages rather than a single 400-mg dose or the saturation of some hepatic metabolic pathway at dosages lower than 200 mg. The mean AUC did, however, consistently show three-to fourfold increases for each dosage evaluated between days 1 and 15, which is characteristic of nonlinear pharmacokinetic behavior.
In addition to the dose dependency of bioavailability described above, we observed significant changes in the pharmacokinetic parameters of kei and CL/f from days 1 to 15 at each dosage regimen studied. Over time, all subjects demonstrated reductions in kel of 43 to 61% and reductions in CL/f of 69 to 80%. Thus, itraconazole hepatic metabolism may be a saturable process which can easily be overcome at the dosages used clinically.
The wide variability in itraconazole concentrations following oral administration was not surprising. Similar variability has been reported with the oral administration of ketoconazole in normal volunteers (3) .
In retrospect, the design of this study might have been improved. We used sequential dosage escalation for each subject, separated by a 2-week washout period between regimens. We do not know whether our results would have been similar if the dosages had been assigned randomly, but we doubt that significant differences would have been observed. In addition, we administered 200 mg twice daily rather than 400 mg as a single daily dose. This dosing scheme required alternative data manipulation, as outlined above, in order to calculate the desired pharmacokinetic parameters for this regimen. In summary, several statements regarding itraconazole pharmacokinetics can be made. (i) Itraconazole demonstrates dose dependency, (ii) the concentrations in plasma observed with chronic dosing (steady state) cannot be predicted from initial oral dosing, and (iii) the route of elimination does not appear to be renal. Further pharmacokinetic analysis of itraconazole will be needed in order to characterize fully the behavior of this new antifungal agent in patient populations.
